The Journal of Pediatrics
Volume 151, Issue 2 , Pages 111-113 , August 2007

Pacing the Marathon: Rate of Decline of Pulmonary Function in Cystic Fibrosis

  • Pamela B. Davis, MD, PhD

      Affiliations

    • Corresponding Author InformationReprint requests: Dr Pamela B. Davis, Case Western Reserve University School of Medicine, Biomedical Research Building CWRU School of Medicine, 2109 Adelbert Road, Cleveland, OH 44106-4948.

References 

  1. Cystic Fibrosis Foundation Patient Registry. 2005 Annual Data Report. Bethesda, Md.
  2. Schluchter MD, Konstan MW, Davis PB. Jointly modeling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med. 2002;21:1271–1287
  3. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, et al. Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis Risk factors for rate of decline in FEV1 in children and adolescents with cystic fibrosis. J Pediatr. 2007;151:134–139
  4. Hibbert ME, Couriel JM, Landau LI. Changes in lung, airway, and chest wall function in boys and girls between 8 and 12 yr. J Appl Physiol. 1984;57:304–308
  5. Hopper JL, Hibbert ME, Macaskill GT, Phelan PD, Landau LI. Longitudinal analysis of lung function growth in healthy children and adolescents. J Appl Physiol. 1991;70:770–777
  6. Hanna GM, Daniels CL, Berend N. The relationship between airway size and lung size. Br J Dis Chest. 1985;79:183–188
  7. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol. 1995;48:1041–1049
  8. Davis PB, Byard PJ, Konstan MW. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res. 1997;41:161–165
  9. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995;332:848–854
  10. Konstan MW, Davis PB. Pharmacological approach for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv Drug Deliv Rev. 2002;54:1409–1423

PII: S0022-3476(07)00327-7

doi: 10.1016/j.jpeds.2007.03.060

The Journal of Pediatrics
Volume 151, Issue 2 , Pages 111-113 , August 2007

Article Tools